3.

Adverse events related to PLD dose (<50 mg/m²and 50 mg/m²) in studies that compared PLD alone with non‐PLD agent/s for relapsed ovarian cancer
Patient or population: women with relapsed ovarian cancer Settings: inpatient or outpatient setting Intervention: PLD Comparison: other non‐PLD drug/s
Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk
	non‐PLD agent/s	PLD alone
SAE: HFS (grade 3) subgrouped by PLD dose	< 50 mg/m²PLD dose every 4 weeks		RR 4.63 (1.32 to 16.19) RR 50.75 (12.57 to 204.97)	1344 (4) 1544 (4)	⊕⊕⊕⊕ high ⊕⊕⊕⊕ high	Tests for subgroup differences were significant (P value 0.01).
	< 1 per 1000	5 per 1000 (1 to16)
	50 mg/m²PLD dose every 4 weeks
	< 1 per 1000	51 per 1000 (13 to 205)
SAE: Stomatitis (grade 3 to 4) subgrouped by PLD dose	<50 mg/m²PLD dose every 4 week		RR 2.22 (0.87 to 5.67) RR 12.19 (4.62 to 32.20)	1283 (4) 1544 (4)	⊕⊕⊕⊕ high ⊕⊕⊕⊕ high	Tests for subgroup differences were significant (P value 0.01).
	1 per 1000	2 per 1000 (1 to 6)
	50 mg/m²PLD dose every 4 weeks
	1 per 1000	12 per 1000 (5 to 32)
*The basis for the assumed risk is the median control group risk across studies. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: confidence interval; RR: risk ratio; PLD: pegylated liposomal doxorubicin
GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate.